Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 19, 2026.

Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19

Bhawna Tomar, Hans-Joachim Anders, Jyaysi Desai and 1 more

Cells · 2020 · CC BY

doi:10.3390/cells9061383

Abstract

The COVID-19 pandemic is progressing worldwide with an alarming death toll. There is an urgent need for novel therapeutic strategies to combat potentially fatal complications. Distinctive clinical features of severe COVID-19 include acute respiratory distress syndrome, neutrophilia, and cytokine storm, along with severe inflammatory response syndrome or sepsis. Here, we propose the putative role of enhanced neutrophil infiltration and the release of neutrophil extracellular traps, complement activation and vascular thrombosis during necroinflammation in COVID-19. Furthermore, we discuss how neutrophilic inflammation contributes to the higher mortality of COVID-19 in patients with underlying co-morbidities such as diabetes and cardiovascular diseases. This perspective highlights neutrophils as a putative target for the immunopathologic complications of severely ill COVID-19 patients. Development of the novel therapeutic strategies targeting neutrophils may help reduce the overall disease fatality rate of COVID-19.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

The novel severe acute respiratory syndrome coronavirus (SARS-CoV)-2 was first discovered in Wuhan, China, and believed to have transmitted from bats to humans. The SARS-CoV-2 has higher human-to-human transmission capabilities compared to the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) and has resulted in a pandemic. The World Health Organization has named the disease COVID-19: coronavirus disease-2019; since it was first reported in December 2019. Although SARS-CoV-2 affects lungs at first, it can extend to many organs, including the heart, kidneys, gut, blood vessels, and the brain.

The SARS-CoV-2 is closely related to the SARS-CoV since they have 80% similarity in genome sequence and seven conserved non-structural domains identified by protein sequence analysis. Moreover, they both have a similar receptor-binding domain, and therefore both use the same cell entry receptor, i.e. angiotensin-converting enzyme II (ACE2). Subsequently, viral replication in combination with the subsequent antiviral immune response both contribute to the severity of COVID-19, which in some patients involves cytokine storm followed by severe inflammatory response syndrome (SIRS), sepsis, multi-organ failure, and death. However, little is known about the immune pathomechanisms that trigger the cytokine storm during COVID-19. We propose that as part of the first line of the innate immune defense, neutrophils are critical for the exacerbation of the immune response, and that neutrophil extracellular traps (NETs)-related necroinflammation plays a central role in the development of the cytokine storm, sepsis and multi-organ failure during COVID-19.

2. ACE2 and Neutrophils

ACE2, a homolog of ACE and central negative regulator of the renin-angiotensin system is a type 1 integral membrane glycoprotein monocarboxypeptidase that converts angiotensin-II (AngII) to Ang-(1–7) and is constitutively expressed by the epithelial cells of the lungs, kidney, heart, and intestines on the outer surface. Ang-(1–7) is a vasodilator that mediates anti-inflammatory, anti-proliferative, and anti-fibrotic effects through the Mas receptor. Using ACE2-mutant mice, Imai, et al. demonstrated protective functions of ACE2 in acute respiratory distress syndrome (ARDS). They observed that ACE2 negatively regulates AngII, and thus, increases vascular permeability, lung edema, and the infiltration of neutrophils, partially mediated by the angiotensin 1 receptor (AT1R). Interestingly, SARS-CoV-infected mice or mice receiving injections of SARS-CoV spike protein showed an aggravated phenotype compared to ACE2-mutant mice, suggesting the contribution of ACE2 beyond being a mere receptor for SARS-CoV. Similar to SARS-CoV, upon binding to ACE2, SARS-CoV-2 enters cells along with ACE2 leading to reduced ACE2 expression on the cell surface. Therefore, the loss of ACE2 might contribute to the severity of ARDS during COVID-19 by increasing AngII- and AT1R-mediated vascular permeability, lung edema, and neutrophils infiltration.

How does ACE2 regulate the infiltration of neutrophils mechanistically? Sodhi et al. demonstrated that attenuation of pulmonary ACE2 activity leads to activation of des-Arg9 bradykinin (DABK)/bradykinin receptor B1 (BKB1R) axis, the release of pro-inflammatory chemokines e.g., C-X-C motif chemokine ligand 5 (CXCL5), macrophage inflammatory protein-2 (MIP2), CXCL1, and tumor necrosis factor (TNF)-α from airway epithelia, increased neutrophil infiltration, and exaggerated endotoxin-induced lung inflammation and injury. The dynamic variation of pulmonary ACE2 was found essential to control neutrophilic inflammation, i.e., a balanced reduction of ACE2 while encountering a bacterial lung infection to recruit inflammatory neutrophils to combat the infection and later its recovery to restrict neutrophil accumulation to alleviate the inflammation by limiting interleukin (IL)-17 signaling by reducing STAT3 pathway activity. Thus, ACE2 prevents the infiltration of neutrophils at the injury or infection site.

3. SARS-CoV-2, Neutrophils, and Necroinflammation in COVID-19

An increased neutrophil-to-lymphocyte ratio predicts severe illness in the early stage of SARS-CoV-2 infection, whereas neutrophilia frequently develops in COVID-19 patients in intensive care units. Being part of the first line of innate immune defense, neutrophils have been thought to have protective roles during bacterial or fungal infections, where they kill bacteria or fungi by phagocytosis as well as NET formation. However, their role in viral infections remains unclear. In murine SARS-CoV infection, neutrophils were dispensable for antibody-mediated clearance of SARS-CoV from pulmonary cells as well as the survival of SARS-CoV-infected mice. On the other hand, continuous infiltration of neutrophils at the site of infection and their degranulation and release of NETs in response to microbial stimuli to raise an immune response produces exaggerated cytokines and chemokine that might result in the “cytokine storm” and contribute to the ARDS, SIRS and sepsis development during COVID-19. Higher levels of interleukin (IL)-1β, interferon-γ, CXCL10, monocyte chemoattractant protein-1, granulocyte colony-stimulating factor, monocyte inhibitory protein-1, and TNF-α were observed in COVID-19 patients requiring ICU admission. A lung autopsy from a patient who succumbed to COVID-19 revealed an extensive neutrophil infiltration in pulmonary capillaries with extravasation into the alveolar space displaying acute capillaritis, as well as neutrophilic mucositis of the trachea indicating inflammation to the entire airway. Moreover, SARS-CoV-2 infection of endothelial cells and the accumulation of inflammatory cells induced endothelitis in multiple organs, which may contribute to the systemic impaired microcirculatory function during COVID-19 and to the phenomenon of the “happy hypoxia”.

The SARS-CoV accessory protein open reading frames SARS3a induced multimodal necrotic cell death in epithelial cells. Interestingly, SARS3a is conserved in SARS-CoV-2, suggesting the engagement of similar pathomechanisms during COVID-19. Cellular necrosis as well as NET formation results in the release of several intracellular danger-associated molecular patterns that activate the pattern recognition receptors on the surrounding immune and non-immune cells resulting in more production of inflammatory cytokines and chemokines. The release of NETs disperses histones, DNA, and granule proteins, such as myeloperoxidase, neutrophil elastase, cathepsin G, and proteinase 3, which results in severe tissue destruction, setting up the auto-amplification loop of necroinflammation (Figure 1).

NETing neutrophils tend to form larger aggregates called “AggNETs” that drive the formation of thrombi in blood vessels. Interestingly, high incidences of venous thrombosis are reported in COVID-19. The extracellular DNA released by NETs activates the platelets, and the AggNETs provide a scaffold for binding of the erythrocytes and activated platelets, which further promote the NET formation and set up a vicious cycle propagating thrombus formation. NETs also activate the complement system. Myeloperoxidase, cathepsin G, and proteinase 3 activate properdin, factor B, and C3, three components of the alternative pathway required to induce the complement cascade. Activated neutrophils also express properdin, factor B, and C3, suggesting an important role of neutrophils in complement activation. Of note, activation of the complement system has been reported in the severe COVID-19 patients. Together, neutrophils infiltration and NETs formation drive necroinflammation during coronavirus infections (Table 1).

4. Diabetes, SARS-CoV-2, and Neutrophils

Many prevalent co-morbidities increase the severity and mortality of COVID-19. One of the most distinctive co-morbidities is diabetes mellitus. Out of 1099 cases reported by Guan et al., 16.2% of patients with severe disease had a higher prevalence of diabetes compared to 5.7% of patients with the non-severe disease. Case fatality was higher in COVID patients with diabetes. This may be attributed to the dysfunctional innate immunity, as well as the exaggerated pro-inflammatory cytokine response in patients with diabetes. Furthermore, higher glucose levels glycosylate and shed ACE2 may contribute to the severity of ARDS during COVID-19 by increasing vascular permeability, edema, and neutrophils infiltration in DM patients. On the other hand, it was believed that patients with diabetes treated with ACE inhibitors and angiotensin-receptor blockers may develop increased ACE2 expression, which could further facilitate the cell entry of SARS-CoV-2 and aggravate the infection. However, a recent study reported no association with the likelihood of COVID-19 positive test or severity of COVID-19 with renin-angiotensin system inhibitors. Hyperglycemia in diabetes primes neutrophils to release NETs that might further contribute to the cytokine storm, SIRS, and sepsis in COVID-19. Besides, sugar-activated neutrophils produce S100 Calcium-binding proteins A8/A9 (S100A8/A9) that increased the production of thrombopoietin in the liver and subsequent thrombocytosis, which might contribute to thrombus formation in COVID-19. Th17-associated cytokine production promoted disease-predictive inflammation in DM. Interestingly, a higher number of CCR6+ TH17 cells were found in the peripheral blood of COVID-19 patients, suggesting critical involvement of TH17 response. Together, neutrophil-mediated cytokine storm leads to sepsis and subsequent multi-organ failure to aggravate the severity of COVID-19 disease.

5. Cardiovascular Diseases, SARS-CoV-2, and Neutrophils

Cardiovascular diseases, including coronary heart disease, cardiomyopathy, arrhythmias, myocardial injury, and hypertension are other distinctive co-morbidities of COVID-19 that have higher overall mortality rates. Especially, the extent of myocardial injury correlated with cardiac dysfunction, arrhythmias, and fatal outcome of COVID-19. ACE2 exerts vasodilatory effects through Ang-(1–7) and the Mas receptor. Therefore downregulation of ACE2 upon SARS-CoV-2 cell entry induces vasoconstriction and subsequent hypertension. Subsequent ACE2-mediated neutrophil infiltration, as well as NET formation, might be responsible for the exaggerated inflammatory response, which in turn contributes to the development of cardiovascular diseases, e.g., thrombosis, atherosclerosis, and endothelial injury, etc. One in five hospitalized COVID-19 patients showed increased troponin, brain natriuretic peptide, lymphopenia, and inflammation markers, such as c-reactive protein, IL-1β, and IL-6 in the early course of the disease suggesting cardiac injury. Recently, NET-related endothelial cell injury was reported to contribute to vascular pathology in pulmonary hypertension. Moreover, IL-1β promoted the thrombus formation via NET-associated tissue factor during atheroembolic events during cardiovascular diseases. Furthermore, increased neutrophil elastase activity was reported to contribute to obesity, insulin resistance, and related inflammation. Interestingly, the presence of obesity in metabolic associated fatty liver disease increased the severity of COVID-19 six-fold. All these reports indicate the involvement of neutrophils and related necroinflammation in the pathology and severity of COVID-19.

6. Summary and Perspectives

To summarize, neutrophils play a central role in the immunopathology of COVID-19. SARS-CoV-2 infection, as well as downregulation of ACE2 upon the cell entry of SARS-CoV-2 triggers neutrophil infiltration in the lungs. Necrotic cell death of alveolar epithelial cells, as well as NET formation, releases damage-associated molecular patterns and alarmins in the surrounding extracellular space, which induce production of pro-inflammatory cytokines and vice versa, setting up a loop of necroinflammation that is responsible for the cytokine storm and sepsis. NETting neutrophils cause endothelial injury and necroinflammation via complement activation, as well as promote the venous thrombus formation during COVID-19. Underlying co-morbidities in COVID-19 patients, e.g., diabetes and cardiovascular diseases enhance the neutrophilic inflammation and thereby severity of COVID-19. Therefore, the development of novel therapeutic strategies targeted at neutrophils, e.g., inhibitors of neutrophil recruitment or NET formation may help reduce the overall disease mortality rate of COVID-19.

References 53

  1. 1.
    A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020
    No notice
  2. 2.

    Wadman M., Couzin-Frankel J., Kaiser J., Matacic C. A rampage through the body. Science. 2020;368:356-360.

    Not in our library10.1126/science.368.6489.356

  3. 3.

    Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395:565-574.

    Not in our library10.1016/s0140-6736(20)30251-8

  4. 4.

    Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260-1263.

    Not in our library10.1126/science.abb2507

  5. 5.

    Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.e278.

    Not in our library10.1016/j.cell.2020.02.052

  6. 6.

    Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.

    Not in our library10.1016/s0140-6736(20)30183-5

  7. 7.

    Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., Yang P., Sarao R., Wada T., Leong-Poi H., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112-116.

    Not in our library10.1038/nature03712

  8. 8.
    The ACE2/Angiotensin-(1–7)/Mas Receptor Axis: Pleiotropic Roles in Cancer · 2017
    Not checked
  9. 9.

    Kuba K., Imai Y., Rao S., Gao H., Guo F., Guan B., Huan Y., Yang P., Zhang Y., Deng W., et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005;11:875-879.

    Not in our library10.1038/nm1267

  10. 10.

    Eguchi S., Kawai T., Scalia R., Rizzo V. Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology. Hypertension. 2018;71:804-810.

    Not in our library10.1161/hypertensionaha.118.10266

  11. 11.

    Sodhi C.P., Wohlford-Lenane C., Yamaguchi Y., Prindle T., Fulton W.B., Wang S., McCray P.B., Chappell M., Hackam D.J., Jia H. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am. J. Physiol. Lung Cell. Mol. Physiol. 2018;314:L17-L31.

    Not in our library10.1152/ajplung.00498.2016

  12. 12.

    Sodhi C.P., Nguyen J., Yamaguchi Y., Werts A.D., Lu P., Ladd M.R., Fulton W.B., Kovler M.L., Wang S., Prindle T., et al. A Dynamic Variation of Pulmonary ACE2 Is Required to Modulate Neutrophilic Inflammation in Response to Pseudomonas aeruginosa Lung Infection in Mice. J. Immunol. 2019;203:3000-3012.

    Not in our library10.4049/jimmunol.1900579

  13. 13.

    Liu Y., Du X., Chen J., Jin Y., Peng L., Wang H.H.X., Luo M., Chen L., Zhao Y. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J. Infect. 2020.

    Not in our library10.1016/j.jinf.2020.04.002

  14. 14.

    Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708-1720.

    Not in our library10.1056/nejmoa2002032

  15. 15.

    Lagunas-Rangel F.A. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J. Med. Virol. 2020.

    Not in our library10.1002/jmv.25819

  16. 16.

    Németh T., Sperandio M., Mócsai A. Neutrophils as emerging therapeutic targets. Nat. Rev. Drug Discov. 2020;19:253-275.

    Not in our library10.1038/s41573-019-0054-z

  17. 17.

    Yasui F., Kohara M., Kitabatake M., Nishiwaki T., Fujii H., Tateno C., Yoneda M., Morita K., Matsushima K., Koyasu S., et al. Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus. Virology. 2014;454–455:157-168.

    Not in our library10.1016/j.virol.2014.02.005

  18. 18.

    Channappanavar R., Fehr A.R., Vijay R., Mack M., Zhao J., Meyerholz D.K., Perlman S. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19:181-193.

    Not in our library10.1016/j.chom.2016.01.007

  19. 19.

    Zuo Y., Yalavarthi S., Shi H., Gockman K., Zuo M., Madison J.A., Blair C.N., Weber A., Barnes B.J., Egeblad M., et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020.

    Not in our library10.1172/jci.insight.138999

  20. 20.

    Barnes B.J., Adrover J.M., Baxter-Stoltzfus A., Borczuk A., Cools-Lartigue J., Crawford J.M., Daßler-Plenker J., Guerci P., Huynh C., Knight J.S., et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J. Exp. Med. 2020;217:e20200652.

    Not in our library10.1084/jem.20200652

  21. 21.

    Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-1418.

    Not in our library10.1016/s0140-6736(20)30937-5

  22. 22.

    Couzin-Frankel J. The mystery of the pandemic’s ‘happy hypoxia’. Science. 2020;368:455-456.

    Not in our library10.1126/science.368.6490.455

  23. 23.
    SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death · 2018
    No notice
  24. 24.

    Linkermann A., Stockwell B.R., Krautwald S., Anders H.J. Regulated cell death and inflammation: An auto-amplification loop causes organ failure. Nat. Rev. Immunol. 2014;14:759-767.

    Not in our library10.1038/nri3743

  25. 25.

    Mulay S.R., Linkermann A., Anders H.J. Necroinflammation in Kidney Disease. J. Am. Soc. Nephrol. 2016;27:27-39.

    Not in our library10.1681/asn.2015040405

  26. 26.

    Nakazawa D., Desai J., Steiger S., Müller S., Devarapu S.K., Mulay S.R., Iwakura T., Anders H.J. Activated platelets induce MLKL-driven neutrophil necroptosis and release of neutrophil extracellular traps in venous thrombosis. Cell Death Discov. 2018;4:6.

    Not in our library10.1038/s41420-018-0073-2

  27. 27.

    Llitjos J.F., Leclerc M., Chochois C., Monsallier J.M., Ramakers M., Auvray M., Merouani K. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J. Thromb. Haemost. 2020.

    Not in our library10.1111/jth.14869

  28. 28.

    de Bont C.M., Boelens W.C., Pruijn G.J.M. NETosis, complement, and coagulation: A triangular relationship. Cell. Mol. Immunol. 2019;16:19-27.

    Not in our library10.1038/s41423-018-0024-0

  29. 29.
    Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage · 2020
    No notice
  30. 30.

    Fu J., Kong J., Wang W., Wu M., Yao L., Wang Z., Jin J., Wu D., Yu X. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. Thromb. Res. 2020;192:3-8.

    Not in our library10.1016/j.thromres.2020.05.006

  31. 31.
    Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis · 2018
    No notice
  32. 32.

    Chen J., Lau Y.F., Lamirande E.W., Paddock C.D., Bartlett J.H., Zaki S.R., Subbarao K. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J. Virol. 2010;84:1289-1301.

    Not in our library10.1128/jvi.01281-09

  33. 33.

    Huang K.J., Su I.J., Theron M., Wu Y.C., Lai S.K., Liu C.C., Lei H.Y. An interferon-gamma-related cytokine storm in SARS patients. J. Med. Virol. 2005;75:185-194.

    Not in our library10.1002/jmv.20255

  34. 34.

    Wong C.K., Lam C.W., Wu A.K., Ip W.K., Lee N.L., Chan I.H., Lit L.C., Hui D.S., Chan M.H., Chung S.S., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004;136:95-103.

    Not in our library10.1111/j.1365-2249.2004.02415.x

  35. 35.

    Wong R.S., Wu A., To K.F., Lee N., Lam C.W., Wong C.K., Chan P.K., Ng M.H., Yu L.M., Hui D.S., et al. Haematological manifestations in patients with severe acute respiratory syndrome: Retrospective analysis. BMJ. 2003;326:1358-1362.

    Not in our library10.1136/bmj.326.7403.1358

  36. 36.

    Li K., Wohlford-Lenane C.L., Channappanavar R., Park J.E., Earnest J.T., Bair T.B., Bates A.M., Brogden K.A., Flaherty H.A., Gallagher T., et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc. Natl. Acad. Sci. USA. 2017;114:3119-3128.

    Not in our library10.1073/pnas.1619109114

  37. 37.
    Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity · 2016
    No notice
  38. 38.

    Baseler L.J., Falzarano D., Scott D.P., Rosenke R., Thomas T., Munster V.J., Feldmann H., de Wit E. An Acute Immune Response to Middle East Respiratory Syndrome Coronavirus Replication Contributes to Viral Pathogenicity. Am. J. Pathol. 2016;186:630-638.

    Not in our library10.1016/j.ajpath.2015.10.025

  39. 39.

    Aldabbous L., Abdul-Salam V., McKinnon T., Duluc L., Pepke-Zaba J., Southwood M., Ainscough A.J., Hadinnapola C., Wilkins M.R., Toshner M., et al. Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension. Arterioscler. Thromb. Vasc. Biol. 2016;36:2078-2087.

    Not in our library10.1161/atvbaha.116.307634

  40. 40.

    Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet. Respir. Med. 2020;8:e21.

    Not in our library10.1016/s2213-2600(20)30116-8

  41. 41.

    Zheng K.I., Gao F., Wang X.B., Sun Q.F., Pan K.H., Wang T.Y., Ma H.L., Liu W.Y., George J., Zheng M.H. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;154244.

    Not in our library10.1016/j.metabol.2020.154244

  42. 42.

    Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. Jama. 2020.

    Not in our library10.1001/jama.2020.2648

  43. 43.

    Wong S.L., Demers M., Martinod K., Gallant M., Wang Y., Goldfine A.B., Kahn C.R., Wagner D.D. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat. Med. 2015;21:815-819.

    Not in our library10.1038/nm.3887

  44. 44.

    Salem E.S., Grobe N., Elased K.M. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am. J. Physiol. Renal. Physiol. 2014;306:F629-F639.

    Not in our library10.1152/ajprenal.00516.2013

  45. 45.

    Reynolds H.R., Adhikari S., Pulgarin C., Troxel A.B., Iturrate E., Johnson S.B., Hausvater A., Newman J.D., Berger J.S., Bangalore S., et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N. Engl. J. Med. 2020.

    Not in our library10.1056/nejmoa2008975

  46. 46.

    Kraakman M.J., Lee M.K., Al-Sharea A., Dragoljevic D., Barrett T.J., Montenont E., Basu D., Heywood S., Kammoun H.L., Flynn M., et al. Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes. J. Clin. Investig. 2017;127:2133-2147.

    Not in our library10.1172/jci92450

  47. 47.

    Nicholas D.A., Proctor E.A., Agrawal M., Belkina A.C., Van Nostrand S.C., Panneerseelan-Bharath L., Jones A.R.t., Raval F., Ip B.C., Zhu M., et al. Fatty Acid Metabolites Combine with Reduced β Oxidation to Activate Th17 Inflammation in Human Type 2 Diabetes. Cell Metab. 2019;30:447-461.

    Not in our library10.1016/j.cmet.2019.07.004

  48. 48.

    Wu D., Yang X.O. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J. Microbiol. Immunol. Infect. 2020.

    Not in our library10.1016/j.jmii.2020.03.005

  49. 49.
    Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) · 2020
    No notice
  50. 50.

    Chapman A.R., Bularga A., Mills N.L. High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight Against COVID-19. Circulation. 2020;141:1733-1735.

    Not in our library10.1161/circulationaha.120.047008

  51. 51.

    Yadav V., Chi L., Zhao R., Tourdot B.E., Yalavarthi S., Jacobs B.N., Banka A., Liao H., Koonse S., Anyanwu A.C., et al. Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1beta-driven venous thrombosis. J. Clin. Investig. 2019;129:2872-2877.

    Not in our library10.1172/jci124804

  52. 52.

    Liberale L., Holy E.W., Akhmedov A., Bonetti N.R., Nietlispach F., Matter C.M., Mach F., Montecucco F., Beer J.H., Paneni F., et al. Interleukin-1beta Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. J. Clin. Med. 2019;8:2072.

    Not in our library10.3390/jcm8122072

  53. 53.

    Mansuy-Aubert V., Zhou Q.L., Xie X., Gong Z., Huang J.Y., Khan A.R., Aubert G., Candelaria K., Thomas S., Shin D.J., et al. Imbalance between neutrophil elastase and its inhibitor α1-antitrypsin in obesity alters insulin sensitivity, inflammation, and energy expenditure. Cell Metab. 2013;17:534-548.

    Not in our library10.1016/j.cmet.2013.03.005

Cited by papers we hold 9

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.